

#240

COMPLETE

Collector: Web Link 1 (Web Link)
Started: Tuesday, August 11, 2026 12:49:04 PM
Last Modified: Tuesday, August 11, 2026 12:54:03 PM
Time Spent: 00:04:59
IP Address: 192.139.231.5

Page 2: Part 1

Q1

Title of activity

CSACI annual conference presentation 2026

Q2

Date of activity

October 15, 2026

Q3

Speaker

What is your role in the CPD activity? (Select all that apply)

Q4

Academic Practice

What's your practice type?

Q5

Please indicate:

I HAVE a relationship with a for-profit and/or a not-for-profit organization to disclose.If so, please indicate below (questions 5 to 10) the organization(s) with which you have/had a relationship over the previous two years and briefly describe the nature of that relationship.

Q6

Respondent skipped this question

Any direct financial payments including receipt of honoraria

Q7

Respondent skipped this question

Membership on advisory boards or speakers' bureaus

Q8

Funded grants or clinical trials

Name of FOR PROFIT and/or NOT-for-profit organization(s)
(separate with commas)**Lung Health Foundation, Children's Hospital Academic
Medical Association, Canadian Institutes of Health
Research**

Description of relationship(s)

Operating grants**Q9**

Patents on a drug, product or device

Respondent skipped this question**Q10**All other investments or relationships that could be seen
by a reasonable, well-informed participant as having the
potential to influence the content of the educational activity**Respondent skipped this question**

Page 3: Part 2: To be completed by presenters only

Q11I intend to use trade names during my presentation. Note:
Only generic names should be used whenever possible. If
trade names are used, they should be accompanied by the
generic name.**No****Q12**I intend to make therapeutic recommendations for
medications that have not received regulatory approval
(i.e. "off-label" use of medication). Note: You must declare
all off-label use to the audience during your presentation.

Yes (please provide a brief description or rationale):

We will be presenting data and recommendations for some
asthma biologic medications that are not yet approved in
Canada and for some medications that are not Health
Canada approved for use in children**Q13**If you answered "Yes" to the previous question, are the
medications recommended manufactured by companies
you have received funding from?**No****Q14**I acknowledge that the National Standard requires that any
description of therapeutic options utilize generic names (or
both generic and trade names) and not reflect exclusivity
and branding.**Yes**

Page 4: Part 3 (Anonymous & Optional): Equity, Diversity and Inclusion (EDI)

Q15

Yes

I confirm that I've completed the EDI Survey linked above

Page 5: PART 4: Acknowledgement and signature (for all)

Q16

First Name:

Dhenuka

Q17

Last Name:

Radhakrishnan

Q18

She/Her

Gender Pronouns - How would you like us to address you?

Q19

Please review and check the items below.

I confirm that the above information is accurate and complete.

,

I understand that this information may be publicly available
